Genomma Lab Internacional Announces Results for the Third Quarter 2025

MEXICO CITY, Oct. 22, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the third quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri

"Genomma Lab reported a challenging third quarter, with like-for-like sales decreasing -2.9%, primarily due to a weak summer season impacting beverage sales in central Mexico and a softer overall consumption environment in the country. Despite topline pressure, Genomma Lab maintained a healthy 23.7% EBITDA margin, underscoring the strength of our business fundamentals, disciplined execution and cost containment throughout our organization. The Company's productivity program, launched in 2023, is expected to generate MXN 3.0 billion in cumulative savings by 2026 including MXN 1.1 billion secured this year. These resources will be reinvested into the business to accelerate topline growth through focused initiatives in product innovation, distribution expansion, pricing, communication and e-commerce, while maintaining an average 24% EBITDA margin. With solid fundamentals and a clear roadmap, Genomma Lab is well-positioned to emerge stronger from this cycle—rebuilding momentum and laying the groundwork for our next phase of sustained growth expected to resume in 1H 2026 following what we anticipate to still be a challenging end of 2025."

Q3 2025 Financial Summary

The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos.

Like-for-like Sales: Decreased by -2.9% primarily due to a tough consumption environment in Mexico and a weak summer season impacting the beverage category in the country, which was partially offset by robust growth in Brazil, Chile, Central America and the Andean cluster. Net sales decreased by -12.8% primarily due to non-cash accumulated hyperinflationary accounting effects related to a -35% Argentine peso depreciation.

EBITDA: Reached a 23.7% margin; a +2 basis-point increase driven by manufacturing cost efficiencies, a favorable sales mix and successful company-wide productivity initiatives—reflecting strong operational resilience despite deleveraging pressures.

Proforma Net income: When excluding non-cash FX related effects, proforma net income decreased by -3.0% reflecting a strong EBITDA margin and lower net interest expenses. Net income decreased by -34.2% primarily due to non-cash accumulated hyperinflationary accounting effects related to a -53% depreciation of the Argentine peso.

Proforma EPS: When excluding non-cash effects, proforma EPS stood at MXN 0.63 per share; a -3.0% increase.

CONFERENCE CALL INFORMATION

Date: Thursday, October 23, 2025

Time: 1:00 p.m. ET | 11:00 a.m. Mexico City Time

Webcast Registration: Genomma's Q3 2025 Earnings Call

Participants:   Marco Sparvieri, CEO
Antonio Zamora, CFO     
Christianne Ibanez, IRO

After registration, please use the Zoom link provided to ensure optimal access to the event webcast and to avoid difficulties associated with local carrier connections.

Sell-side Analyst Coverage

As of October 22, 2025 "LABB" is covered by 8 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities and Monex Grupo Financiero.

About
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LAB B" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab Internacional, S.A.B. de C.V.